
Volume 38 · Number 1
JANUARY 2008
Long-term Efficacy of ADHD Pharmacotherapy in Children
By
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobehavioral disorder with core symptoms of inattention, overactivity, and impulsivity that adversely affect many domains of function across the lifespan. Numerous short-term studies confirm decrease in core symptoms from pharmacotherapy, primarily stimulants, and more recently atomoxetine. Despite ADHD being a chronic disorder and ADHD pharmacotherapy being one of the most researched topics in child psychiatry, long-term efficacy has been examined only recently. Efficacy for core symptoms through 15 months appears well established, and there is reasonable evidence through 2 years for continued efficacy in some patients. However, evidence beyond 2 years is scant and confounded with self-selection for continuation. In general, evidence for benefit in associated domains (social skills, achievement, family function, internalizing symptoms) is not as impressive as for core symptoms, but there appears to be some benefit through 14 months and possibly 2 years of treatment. The long-term examination of efficacy is complicated by the presence/development of co-morbidities, poor follow-up, poor adherence to prescribed regimens, and the healthcare system’s inability to provide prolonged, careful medication management. Future studies are needed to examine the longer-term (beyond 2 years) effects of medication management when provided at optimal, carefully monitored levels.
ABOUT THE AUTHORS
Richard H. Gilchrist, MD, is Child Psychiatrist, Nationwide Children’s Hospital, and Clinical Assistant Professor, Department of Psychiatry, The Ohio State University. L. Eugene Arnold, MD, is Professor Emeritus, Department of Psychiatry, The Ohio State University.
Address correspondence to: Richard H. Gilchrist, MD, Nationwide Children’s Hospital, 700 Children’s Drive, Timken Hall H 206, Columbus OH 43054; [email protected].
Dr. Gilchrist has disclosed no relevant financial relationships. Dr. Arnold has disclosed the following relevant financial relationships: Organon, Novartis, and Shire: Consultant; Bristol-Myers Squibb, Eli Lilly, and Shire: Research funding recipient; and McNeil, Novartis, and Shire: Member of Speakers’ Bureau.
EDUCATIONAL OBJECTIVES
- Review the core symptoms of ADHD and discuss prevalence estimates in children and adolescents.
- Discuss the findings of the Multi-Modal Treatment Study of ADHD (MTA) Cooperative Group and how they relate to the long-term efficacy of stimulant medications in children and adolescents.
- Determine the current evidence for the effect of long-term stimulant medication on substance abuse, accidents, risk taking behavior, and quality of life scores in children and adolescents with ADHD.
This CME activity is primarily targeted to patient-caring physicians specializing in psychiatry. Physicians can receive AMA PRA Category 1 Credits™ by reading the CME articles in Psychiatric Annals and successfully completing the quiz at the end of the articles. Complete instructions are given subsequently. Educational objectives are found at the beginning of each CME article.
CME ACCREDITATION
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Vindico Medical Education and Psychiatric Annals. Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Vindico Medical Education designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
FULL DISCLOSURE POLICY
In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears at the beginning of each CME-accredited article in this issue.
UNLABELED AND INVESTIGATIONAL USAGE
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
RESPONSIBILITY FOR STATEMENTS
All opinions expressed by authors and quoted sources are their own and do not necessarily reflect the opinions of the editors, publishers, or editorial boards of Psychiatric Annals or its employees, Vindico Medical Education or its employees, or the University of New Mexico. The acceptance of advertising in no way implies endorsement by the editors, publishers, or editorial boards of Psychiatric Annals.
The material presented at or in any Psychiatric Annals or Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education or Psychiatric Annals. Neither Psychiatric Annals, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. Articles are intended for informational purposes only and should not be used as the basis of patient treatment. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Copyright © 2008 by SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without prior written consent of the publisher.
INSTRUCTIONS
- Review the stated learning objectives of the CME articles and determine if these objectives match your individual learning needs. You must read each of the CME articles in this issue carefully in order to take the quiz. Do not neglect the tables and other illustrative materials as they have been selected to enhance your knowledge and understanding.
- The cost of taking the CME quiz is $25; you must pay this fee prior to completing the quiz online.
- The quiz questions have been designed to provide a useful link between the CME articles in the issue and your everyday practice. Read each question and choose the correct answer by checking the box next to your desired answer.
- After you answer all questions, your quiz is graded. A score of at least 80% is required to pass
- If you passed the quiz, you will receive by mail a CME certificate of within 4 to 6 weeks. If you failed the quiz, you may retake the quiz at another time by returning to the CME articles and then registering again for the quiz.

Please note, you must read all CME articles in this issue to take the CME Quiz.
The Devastation and Pain of ADHD
Jan Fawcett, MD
Attention-Deficit/Hyperactivity Disorder
Mark L. Wolraich, MD
Function, Impairment, and Long-term Outcomes in Children with ADHD and How to Measure Them
Donald J. Lollar, EdD
Approaching ADHD as a Chronic Condition: Implications for Long-term Adherence
Jeanne Van Cleave, MD;
Laurel K. Leslie, MD, MPH
Long-term Safety of Stimulant Medications Used to Treat Children with ADHD
Marc Lerner, MD;
Tim Wigal, PhD
Safety and Efficacy of Psychosocial Interventions Used to Treat Children with Attention-Deficit/Hyperactivity Disorder
Steven W. Evans, PhD;
Brandon K. Schultz, EdS;
Joanna M. Sadler, BS




